A randomized phase 1 single-dose polysomnography study of ASP8062, a GABA B receptor positive allosteric modulator
ConclusionsSingle-dose ASP8062 (35 and 70 mg) appeared to result in CNS penetration and enhanced GABAergic activity as measured by increases in slow-wave sleep and growth hormone release.
Source: Psychopharmacology - Category: Psychiatry Source Type: research
More News: Headache | Hormones | Migraine | Paroxetine | Paxil | Psychiatry | Sleep Disorders | Sleep Medicine | Study